[The effect of the dopamine D2 receptor agonist cabergoline on the content of catecholamines and expression of BDNF mRNA in the rat midbrain and hypothalamus].

Autor: Anokhin PK; Nationa Research Center on Addiction - The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow, Russia., Veretinskaya AG; Nationa Research Center on Addiction - The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow, Russia., Pavshintsev VV; Lomonosov Moscow State University, Moscow, Russia., Shamakina IY; Nationa Research Center on Addiction - The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow, Russia.
Jazyk: ruština
Zdroj: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2019; Vol. 119 (11), pp. 54-59.
DOI: 10.17116/jnevro201911911154
Abstrakt: Aim: To study an effect of cabergoline on dopamine and noradrenaline concentration and BDNF mRNA level in the rat midbrain and hypothalamus.
Material and Methods: Twenty adult male Wistar rats were used in a single treatment paradigm: animals of the treatment group (n=10) received cabergoline (i.p., 0.5 mg/kg) and the control group (n=10) received an equivalent volume of the solvent. Quantitative analysis for the dopamine (DA) and noradrenaline (NA) was carried out using high-performance liquid chromatography (HPLC) coupled with electrochemical detection. BDNF mRNA levels were studied using quantitative RT-PCR.
Results and Conclusion: Cabergoline significantly increases NA concentration in the midbrain 24 hours after injection: 639.2±64.5 ng/g in the treatment group versus 398.0±66.0 ng/g in the control group (p<0.05), while mean content of DA is not significantly changed (211.4±16.3 ng/g vs 169.7±54.6 ng/g, respectively). Cabergoline does not affect hypothalamic DA and NA levels. The drug increases BDNF mRNA levels by 2-times in the midbrain, but not in the hypothalamus, 24 hours after injection.
Databáze: MEDLINE
Externí odkaz: